Moleculin Biotech Inc Total Liabilities
Moleculin Biotech Inc total liabilities. Based on the latest financial reports, Moleculin Biotech Inc (MBRX) has total liabilities worth $7.12 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Moleculin Biotech Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Moleculin Biotech Inc (2015–2025)
Total liabilities of Moleculin Biotech Inc from 2015 to 2025. This chart illustrates how Moleculin Biotech Inc's total liabilities have evolved over time, based on quarterly financial data.
Moleculin Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Moleculin Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Hain Celestial Group Inc
NASDAQ:HAIN
|
USA | $947.17 Million |
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:PHH
|
USA | $1.58 Million |
|
Stallion Uranium Corp.
V:STUD
|
Canada | CA$3.60 Million |
|
Dyadic International Inc
NASDAQ:DYAI
|
USA | $9.07 Million |
|
Reborn Coffee Inc
NASDAQ:REBN
|
USA | $11.07 Million |
|
Scilex Holding Company
NASDAQ:SCLX
|
USA | $564.05 Million |
|
Nafpaktos Textile Industry S.A
AT:NAYP
|
Greece | €18.91 Million |
|
Imexhs Ltd
AU:IME
|
Australia | AU$8.36 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Moleculin Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Moleculin Biotech Inc.
Liquidity & Leverage Metrics
Moleculin Biotech Inc Total Liabilities Ratios Explained
Moleculin Biotech Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Moleculin Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Moleculin Biotech Inc (2015–2025)
The table below shows the annual total liabilities of Moleculin Biotech Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.12 Million | -34.95% |
| 2024-12-31 | $10.95 Million | -9.86% |
| 2023-12-31 | $12.14 Million | +132.15% |
| 2022-12-31 | $5.23 Million | +2.63% |
| 2021-12-31 | $5.10 Million | -54.78% |
| 2020-12-31 | $11.27 Million | +16.63% |
| 2019-12-31 | $9.66 Million | +81.89% |
| 2018-12-31 | $5.31 Million | +124.65% |
| 2017-12-31 | $2.37 Million | +65.09% |
| 2016-12-31 | $1.43 Million | +85.38% |
| 2015-12-31 | $772.79K | -- |
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more